• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ancora Nominates Four Highly Qualified, Independent Director Candidates and Urges Orderly CEO Succession at Elanco Animal Health

    2/29/24 8:00:00 AM ET
    $ABT
    $CHRW
    $ELAN
    $FWRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Oil Refining/Marketing
    Consumer Discretionary
    Get the next $ABT alert in real time by email

    Believes Slate Possesses Necessary Experience in Capital Allocation, Corporate Governance, Pet Healthcare, Supply Chain Management and Succession Planning

    Contends the Upcoming Annual Meeting is the Ideal Moment to Introduce Truly Independent Directors and Start a Boardroom Dialogue Around a Properly Timed CEO Change in 2025

    Reminds Shareholders That Elanco's Leadership Has Failed to Deliver Value and Meet its Own Promises Over Every Long-Term Horizon

    Urges Shareholders to Review Presentation Regarding the Case for Shareholder-Driven Change Atop Elanco

    Ancora Holdings Group, LLC (together with its affiliates, "Ancora" or "we"), which owns approximately 3% of the outstanding common stock of Elanco Animal Health Incorporated (NYSE:ELAN) ("Elanco" or the "Company"), today issued the below statement regarding its nomination of four highly qualified, independent candidates for election to the Company's Board of Directors (the "Board") at the 2024 Annual Meeting of Shareholders (the "Annual Meeting"). Ancora has also released a presentation, entitled "Overview: The Case for Change at Elanco's 2024 Annual Meeting," which can be viewed and downloaded here.

    "Ancora has amassed a roughly $250 million stake in Elanco because we believe it is a high-potential business with an admirable mission, strong market opportunity and significant runway for sustained value creation. Based on extensive analysis and good faith engagement with Elanco, it appears that the biggest barriers to success are the Company's insular Board and unaccountable CEO. It is important to stress that we provided Elanco with a detailed analysis of its issues pertaining to corporate governance, finance, operations and product development, while also privately proposing a settlement framework that accounted for a shareholder-driven refreshment of the Board and an orderly succession process in 2025 for long-serving CEO Jeff Simmons. Unfortunately, this framework seemed to be of no interest to the Board, which refused to engage in substantive principal-to-principal negotiations and a real two-way discussion regarding changes that would benefit the Company. We can only assume that the Board feels insulated because of its classified structure and shareholder-unfriendly policies, despite overseeing a more than 50% decline in value since inception.

    We believe Elanco's Board should be operating with humility and an open mind after presiding over anemic margins, ballooning debt, poor capital allocation and shoddy forecasting. All of this has translated to negative total shareholder returns over every relevant long-term period, including since inflection points such as the Company's 2018 initial public offering, 2020 acquisition of Bayer Animal Health and 2021 announcement of structural changes to simplify the organization. This is why when Elanco once again claims to be at an ‘inflection point' due to reactionary governance changes and recent stock price movement, we are compelled to point out that the Company is really just being picked up off the mat by Ancora. Elanco's stock price began rising late last year as we increased our investment and the market became aware of potential shareholder-driven changes at the Company.

    We anticipate that the Board and Mr. Simmons will try to avoid accountability by suggesting that an orderly management change will disrupt the Company's pipeline. Shareholders, however, should consider a few key points before buying into this. First, a planned departure in 2025 positions Mr. Simmons to remain engaged during upcoming product launches, even as the Board commits to planning for a transition. Second, shareholders are actually de-risked if Mr. Simmons – who has not overseen any value creation at Elanco – is gradually less involved in product strategy and pipeline oversight. Lastly, team members such as EVPs Ellen de Brabander, Ph.D. and Tim Bettington are really the key leaders of upcoming launches.

    As evidenced by our emphasis on the next generation and willingness to have a principal on the Board, we look forward to being a long-term shareholder of Elanco. We have identified areas in which prior campaigns for change at the Company may have fallen short. Our slate possesses sorely needed experience in capital allocation, corporate governance, pet healthcare, supply chain management and succession planning. Each of our director candidates looks forward to engaging with Elanco shareholders about their constructive and practical ideas for igniting a turnaround at the Company and identifying its next generation of management. If elected by shareholders, rest assured our nominees intend to put this contest in the rearview mirror and support the type of collegial boardroom dialogue that is necessary to unlocking the full potential of Elanco."

    DIRECTOR CANDIDATE BIOS

    Kathy Turner

    Ms. Turner is a successful pet healthcare executive with significant global experience in both the animal health and broader healthcare industries.

    • Previously held senior leadership positions in international commercial operations at IDEXX Laboratories (NASDAQ:IDXX), a global pet healthcare innovation company, from 2014 to 2023, including most recently serving as Global Chief Marketing Officer.
    • Previously held various leadership roles during her nearly 30-year tenure at Abbott Laboratories (NYSE:ABT), a multinational medical devices and healthcare company where she most recently led commercial operations for Europe.
    • Previously served on the Executive Leadership Team of Health for Animals, an organization that focuses on animal health products and animal well-being, and the Nutrition and Technology Innovation Advisory Board of Kiasco Animal Health, an animal health event series that connects innovation and investments.
    • Currently on the board of directors of Veterinarians Without Borders, an organization that promotes animal well-being, human health and economic development domestically and internationally.

    Craig Wallace

    Mr. Wallace is an experienced animal health and veterinary executive, most recently leading one of the largest animal health companies in the world.

    • Former Chief Executive Officer (North America/Pacific) of Ceva Santé Animale, the fifth largest animal health company worldwide.
    • Previously held leadership roles at Trupanion, Inc. (NASDAQ:TRUP), a pet insurance provider, and Fort Dodge Animal Health, a global manufacturer of animal health products for the livestock, companion animal, equine, swine and poultry industries.
    • Currently runs an animal health and human healthcare investment firm and serves on the boards of directors of companies including 1C, a pet retail distributor, and KeraVet Bio, a veterinary wound care company.
    • Previously served on the boards of directors of organizations including the National Commission on Veterinary Economic Issues and the Kansas City Animal Health Corridor Advisory Board.

    James Chadwick

    Mr. Chadwick, a representative of the nominating shareholder, possesses additive experience in capital allocation, finance and strategic restructurings, and executive succession processes.

    • Current President of Ancora Alternatives LLC, where he manages approximately $1.5 billion in capital for partners that include pensions, foundations, and institutional and individual clients.
    • Seasoned investor with a track record of helping companies implement positive and long-lasting governance enhancements, including de-classifications, voting standard changes and director refreshments.
    • Former Senior Analyst at Relational Investors LLC, a pioneer in constructivist investing.
    • Previously served on the boards of directors of companies that include Stewart Information Services Corporation (NYSE:STC), Hill International, Inc. (NYSE:HIL) and Riverview Bancorp, Inc. (NASDAQ:RVSB).

    Andrew Clarke

    Mr. Clarke is a proven corporate leader and supply chain expert with experience in areas that include capital allocation, cost management initiatives, corporate governance and executive succession planning.

    • Current Chairman of Global Critical Logistics, a provider of freight forwarding and logistics.
    • Former Chief Financial Officer of C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW), a global logistics company.
    • Former Chief Financial Officer of Forward Air Corporation (NASDAQ:FWRD), an asset-light freight and logistics company, and former President and Chief Executive Officer of Panther Expedited Services (n/k/a Panther Premium Logistics).
    • Currently serves on the board of directors of Element Fleet Management Corp. (TSX:EFN), where he serves on the Audit Committee and Credit and Risk Committee.
    • Previously served on the boards of directors of companies that include Logistics Innovation Technologies Corp. (NASDAQ:LITT), Oregon Tool ((f/k/a Blount International, NYSE:BLT) and Pacer International, Inc. (NASDAQ:PACR).

    ***

    About Ancora

    Founded in 2003, Ancora Holdings Group, LLC offers integrated investment advisory, wealth management, retirement plan services and insurance solutions to individuals and institutions across the United States. The firm is a long-term supporter of union labor and has a history of working with union groups and public pension plans to deliver long-term value. Ancora's comprehensive service offering is complemented by a dedicated team that has the breadth of expertise and operational structure of a global institution, with the responsiveness and flexibility of a boutique firm. For more information about Ancora, please visit https://ancora.net.

    Advisors

    Wilson Sonsini Goodrich & Rosati is serving as legal advisor to Ancora, with Longacre Square Partners LLC serving as communications and strategy advisor and Saratoga Proxy Consulting, LLC serving as proxy solicitor.

    CERTAIN INFORMATION CONCERNING THE PARTICIPANTS

    Ancora Alternatives LLC ("Ancora Alternatives") and the other Participants (as defined below) intend to file a preliminary proxy statement and accompanying BLUE universal proxy card with the Securities and Exchange Commission to be used to solicit proxies for, among other matters, the election of its slate of director nominees at the 2024 annual meeting of shareholders (the "2024 Annual Meeting") of Elanco Animal Health Incorporated, an Indiana corporation (the "Corporation").

    The participants in the proxy solicitation are currently anticipated to be Ancora Catalyst Institutional, LP ("Ancora Catalyst Institutional"), Ancora Catalyst, LP ("Ancora Catalyst"), Ancora Merlin Institutional, LP, ("Ancora Merlin Institutional"), Ancora Merlin, LP ("Ancora Merlin"), Ancora Bellator Fund, LP ("Ancora Bellator"), Ancora Impact Fund LP Series Z ("Ancora Impact" and together with Ancora Catalyst Institutional, Ancora Merlin Institutional, Ancora Merlin, Ancora Catalyst, Ancora Bellator, Ancora Impact, collectively, the "Ancora Funds"), Ancora Alternatives, Ancora Holdings Group, LLC ("Ancora Holdings") and Frederick DiSanto (collectively, the "Ancora Parties"); and James Chadwick, Andrew C. Clarke, Kathy V. Turner and Craig S. Wallace (the "Ancora Nominees" and, collectively with the Ancora Parties, the "Participants").

    Ancora Catalyst Institutional beneficially owns directly 2,230,542 shares of the Corporation's common stock, no par value (the "Common Stock"). Ancora Catalyst beneficially owns directly 231,370 shares of Common Stock. Ancora Merlin Institutional beneficially owns directly 2,231,680 shares of Common Stock. Ancora Merlin beneficially owns directly 209,163 shares of Common Stock. Ancora Bellator beneficially owns directly 582,569 shares of Common Stock. Ancora Impact beneficially owns directly 4,757,777 shares of Common Stock. Ancora Alternatives SMAs collectively beneficially owns directly 2,664,550 shares of Common Stock (consisting of shares of Common Stock held in certain separately managed accounts, collectively, the "Ancora Alternatives SMAs"). Ancora Alternatives, as the general partner and investment manager of each of the Ancora Funds, may be deemed to beneficially own the 12,907,651 shares of Common Stock beneficially owned in the aggregate by the Ancora Funds and held in the Ancora Alternatives SMAs (including the 2,328,300 shares of Common Stock underlying 22,883 American call options and 400 American style put options). Ancora Holdings, as the sole member of Ancora Alternatives, may be deemed to beneficially own the 12,907,651 shares of Common Stock beneficially owned in the aggregate by the Ancora Funds and held in the Ancora Alternatives SMAs (including the 2,328,300 shares of Common Stock underlying 22,883 American call options and 400 American style put options). Frederick DiSanto, as the Chairman and Chief Executive Officer of Ancora Holdings, may be deemed to beneficially own the 12,907,651 shares of Common Stock beneficially owned in the aggregate by the Ancora Funds and held in the Ancora Alternatives SMAs (including the 2,328,300 shares of Common Stock underlying 22,883 American call options and 400 American style put options). The Ancora Parties beneficially own 12,907,651 shares of Common Stock in the aggregate (including the 2,328,300 shares of Common Stock underlying 22,883 American call options and 400 American style put options). None of the Ancora Nominees beneficially own any shares of Common Stock. All of the foregoing information is as of the date hereof unless otherwise disclosed.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240229862234/en/

    Get the next $ABT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ABT
    $CHRW
    $ELAN
    $FWRD

    CompanyDatePrice TargetRatingAnalyst
    IDEXX Laboratories Inc.
    $IDXX
    7/1/2025$625.00Buy
    Jefferies
    C.H. Robinson Worldwide Inc.
    $CHRW
    7/1/2025$105.00Neutral
    Robert W. Baird
    C.H. Robinson Worldwide Inc.
    $CHRW
    7/1/2025$112.00Peer Perform → Outperform
    Wolfe Research
    Forward Air Corporation
    $FWRD
    6/26/2025$29.00Hold → Buy
    Stifel
    Elanco Animal Health Incorporated
    $ELAN
    6/26/2025Mkt Perform → Outperform
    William Blair
    Abbott Laboratories
    $ABT
    6/16/2025$143.00Market Perform
    Leerink Partners
    C.H. Robinson Worldwide Inc.
    $CHRW
    5/1/2025$111.00 → $112.00Hold
    TD Cowen
    C.H. Robinson Worldwide Inc.
    $CHRW
    3/13/2025$115.00Buy
    Truist
    More analyst ratings

    $ABT
    $CHRW
    $ELAN
    $FWRD
    SEC Filings

    See more
    • IDEXX Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

      7/10/25 7:00:41 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 POS filed by Forward Air Corporation

      S-8 POS - FORWARD AIR CORP (0000912728) (Filer)

      6/30/25 4:20:02 PM ET
      $FWRD
      Oil Refining/Marketing
      Consumer Discretionary
    • SEC Form S-8 POS filed by Forward Air Corporation

      S-8 POS - FORWARD AIR CORP (0000912728) (Filer)

      6/30/25 4:19:01 PM ET
      $FWRD
      Oil Refining/Marketing
      Consumer Discretionary

    $ABT
    $CHRW
    $ELAN
    $FWRD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

      For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

      10/24/23 3:52:17 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $CHRW
    $ELAN
    $FWRD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

      7/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

      IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro

      7/10/25 7:00:00 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection

      TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8.100% virus neutralization against 33 current field isolates.1Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.2,3,4TruCan Ultra CIV completes Elanco's extensive line of Tru Portfolio vaccines.GREENFIELD, Ind., July 9, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine designed to provide broad respiratory disease protection. The approval of TruCan

      7/9/25 8:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $CHRW
    $ELAN
    $FWRD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT/CEO - TRUST CO. Sowers Courtney Evan bought $1,066 worth of shares (196 units at $5.44), increasing direct ownership by 1% to 19,666 units (SEC Form 4)

      4 - RIVERVIEW BANCORP INC (0001041368) (Issuer)

      6/13/25 11:15:45 AM ET
      $RVSB
      Savings Institutions
      Finance
    • EVP/COO Cox Daniel D bought $2,995 worth of shares (560 units at $5.35), increasing direct ownership by 0.82% to 68,964 units (SEC Form 4)

      4 - RIVERVIEW BANCORP INC (0001041368) (Issuer)

      6/5/25 6:47:00 PM ET
      $RVSB
      Savings Institutions
      Finance
    • EVP/CRDEO Lightheart Charmaine bought $2,713 worth of shares (498 units at $5.45), increasing direct ownership by 8% to 6,972 units (SEC Form 4)

      4 - RIVERVIEW BANCORP INC (0001041368) (Issuer)

      6/3/25 5:06:39 PM ET
      $RVSB
      Savings Institutions
      Finance

    $ABT
    $CHRW
    $ELAN
    $FWRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF ACCOUNTING OFFICER Meer James M covered exercise/tax liability with 1,161 shares, decreasing direct ownership by 2% to 58,103 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      7/8/25 4:19:02 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, MANUFACTURING AND QUALITY Mcardle Grace covered exercise/tax liability with 4,346 shares, decreasing direct ownership by 5% to 76,049 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      7/8/25 4:17:14 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Goodburn Mark A.

      4 - C. H. ROBINSON WORLDWIDE, INC. (0001043277) (Issuer)

      7/3/25 4:45:05 PM ET
      $CHRW
      Oil Refining/Marketing
      Consumer Discretionary

    $ABT
    $CHRW
    $ELAN
    $FWRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on IDEXX Labs with a new price target

      Jefferies initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $625.00

      7/1/25 8:38:56 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Robert W. Baird resumed coverage on C.H. Robinson with a new price target

      Robert W. Baird resumed coverage of C.H. Robinson with a rating of Neutral and set a new price target of $105.00

      7/1/25 8:31:06 AM ET
      $CHRW
      Oil Refining/Marketing
      Consumer Discretionary
    • C.H. Robinson upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded C.H. Robinson from Peer Perform to Outperform and set a new price target of $112.00

      7/1/25 8:10:01 AM ET
      $CHRW
      Oil Refining/Marketing
      Consumer Discretionary

    $ABT
    $CHRW
    $ELAN
    $FWRD
    Leadership Updates

    Live Leadership Updates

    See more
    • IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

      IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro

      7/10/25 7:00:00 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Forward Air Corporation Announces Results of 2025 Annual Meeting and Board Changes

      Shareholders Approve Reincorporation to Delaware Forward Air Corporation (NASDAQ:FWRD) (the "Company", "Forward Air", "we", "our", or "us") today announced changes to its Board of Directors following the Company's 2025 Annual Meeting of Shareholders. Under the Company's Corporate Governance Guidelines, the Forward Air Board of Directors has accepted the resignation of George Mayes, effective immediately. While Javier Polit and Laurie Tucker received the support of a majority of the votes cast by shareholders in their election, both have voluntarily resigned as members of the Board, effective immediately, in order to permit the Board and management to continue focusing on the Company's ope

      6/12/25 8:00:00 AM ET
      $FWRD
      Oil Refining/Marketing
      Consumer Discretionary
    • Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

      The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

      6/5/25 7:45:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $CHRW
    $ELAN
    $FWRD
    Financials

    Live finance-specific insights

    See more
    • Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

      7/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • C.H. Robinson Second Quarter 2025 Earnings Release and Conference Call Scheduled for Wednesday, July 30, 2025

      C.H. Robinson Worldwide, Inc. ("C.H. Robinson") (NASDAQ:CHRW), announced today that it will issue its second quarter 2025 results after the market closes on Wednesday, July 30, 2025. The company will hold a conference call from 5:00 pm - 6:00 pm Eastern Time on the same day to discuss the quarterly results and answer live questions from the investment community. Presentation slides and a simultaneous audio webcast of the conference call may be accessed at http://investor.chrobinson.com. To participate in the conference call by telephone, please call ten minutes early by dialing 877-269-7756. An audio replay will be available at http://investor.chrobinson.com. About C.H. Robinson C.H

      7/8/25 8:30:00 AM ET
      $CHRW
      Oil Refining/Marketing
      Consumer Discretionary
    • Riverview Bancorp Declares Quarterly Cash Dividend of $0.02 Per Share

      VANCOUVER, Wash., June 27, 2025 (GLOBE NEWSWIRE) -- Riverview Bancorp, Inc. (Nasdaq GSM: RVSB) ("Riverview" or the "Company") today announced that on June 26, 2025, its Board of Directors approved a quarterly cash dividend of $0.02 per share which remained unchanged compared to the preceding quarter. The dividend is payable on July 22, 2025, to shareholders of record as of July 10, 2025. About Riverview Riverview Bancorp, Inc. (www.riverviewbank.com) is headquartered in Vancouver, Washington – just north of Portland, Oregon, on the I-5 corridor. With assets of $1.51 billion at March 31, 2025, it is the parent company of Riverview Bank, as well as Riverview Trust Company. The Bank offers

      6/27/25 9:00:00 AM ET
      $RVSB
      Savings Institutions
      Finance

    $ABT
    $CHRW
    $ELAN
    $FWRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Riverview Bancorp Inc

      SC 13D/A - RIVERVIEW BANCORP INC (0001041368) (Subject)

      11/21/24 4:55:24 PM ET
      $RVSB
      Savings Institutions
      Finance
    • Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

      SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

      11/12/24 3:48:28 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Forward Air Corporation

      SC 13G/A - FORWARD AIR CORP (0000912728) (Subject)

      11/12/24 2:27:53 PM ET
      $FWRD
      Oil Refining/Marketing
      Consumer Discretionary